Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 07, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
Esperion Reports First Quarter 2024 Financial Results
May 07, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43%...
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
May 07, 2024 04:09 ET
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET
|
Corvus Pharmaceuticals, Inc.
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell...
Sportradar Appoints Behshad Behzadi as Company’s Chief Technology Officer and Chief Artificial Intelligence Officer
May 01, 2024 03:30 ET
|
Sportradar AG
ST. GALLEN, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”) today announced that Behshad Behzadi has been named Chief Technology...
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
April 30, 2024 07:30 ET
|
Tenax Therapeutics
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection...
Sportradar to Release First Quarter Financial Results on May 15, 2024
April 25, 2024 08:30 ET
|
Sportradar AG
ST. GALLEN, Switzerland, April 25, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar”) will release its financial and operating results for the first quarter ended March 31,...
Sportradar Appoints Craig Felenstein as Chief Financial Officer
April 25, 2024 08:00 ET
|
Sportradar AG
ST. GALLEN, Switzerland, April 25, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD)(“Sportradar” or the “Company”) today announced that Craig Felenstein has been named Chief Financial...
Preliminary Results for the Year Ended 31 December 2023
April 19, 2024 08:00 ET
|
Biodexa Pharmaceuticals PLC
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa...
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
April 18, 2024 09:11 ET
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...